Multicenter, Randomised, Double Blind, Placebo-controlled Trial of Golimumab a fully human anti TNF alpha monoclonal antibody, administered subcutaneously in subjects with active Rheumatoid Arthritis and Previously treated with Biological Anti-TNF alpha agents